Skip to main content
Premium Trial:

Request an Annual Quote

Casdin Appointed to NCGR Board of Directors

Premium

SANTA FE, NM--The National Center for Genome Resources, a nonprofit provider of bioinformatics tools and public databases here, appointed Jeffrey Casdin, CEO of Casdin Capital Partners, to its board of directors. Casdin has been engaged in investment analysis of the biotechnology industry since 1985 as a publisher, research analyst, and portfolio manager. He has managed Casdin Capital Partners in New York since early 1997, and previously served as a first vice-president responsible for biotechnology investment research at Merrill Lynch, and as senior vice-president and managing director of Oppenheimer overseeing biotechnology research.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.